This compound, with the CAS number 1358581-37-9, is a complex organic molecule featuring a glycosyl moiety (tetrahydro-2H-pyran-3,4,5-triol) linked to a substituted biphenyl-thiophene core. It is a key intermediate in the synthesis of Sotagliflozin (also known as LX4211), a dual sodium-glucose co-transporter 1 and 2 (SGLT1/SGLT2) inhibitor. Sotagliflozin is an investigational oral antidiabetic drug developed for the treatment of type 1 and type 2 diabetes. This specific intermediate is crucial in constructing the active pharmaceutical ingredient (API) that works by inhibiting glucose reabsorption in the kidneys and intestines, thereby lowering blood glucose levels. Its synthesis represents a critical step in the manufacturing process of this therapeutic agent. As a high-value synthetic intermediate, it is primarily of interest in pharmaceutical research, development, and production. Handling requires standard laboratory precautions for organic compounds, and its use is strictly within the context of controlled pharmaceutical synthesis.